Our results suggest that pharmacological co-activation of KCNN4 K+ channels may augment therapeutic effects of CFTR potentiator and corrector compounds that are currently in active preclinical and clinical development, and suggest KCNN4 as a therapeutic target for CF. This evidence concerns the gene KCNN4 and cystic fibrosis.